Sol-gel synthesis, physicochemical characteristics and in vitro pH-responsive metformin drug release of uniformly polydopamine coated mesoporous silica nanospheres
Source abstract
Abstract
A recent attention has been paid to the repurposing potential of metformin drug for cancer chemotherapy. Herein, pH-responsive metformin drug delivery nanocarriers were achieved using sol-gel synthesized mesoporous silica nanospheres (MSN) uniformly coated with polydopamine (PDA) shell. The PDA coating shell around the MSN surface was in situ formed through oxidative self-polymerization of dopamine monomers in an alkaline solution at room temperature. The microstructure, structural and textural characteristics of PDA@MSN were examined and compared to uncoated MSN. Furthermore, PDA coated metformin (MET) drug-loaded MSN were used to study the pH-responsive MET drug release behaviour under neutral and acidic conditions. The in vitro release test showed that the PDA coating shell not only protects MET drug leakage under normal physiological conditions (pH 7.4) but also allows for its controlled/sustained release in acidic conditions (pH 4.5 and pH 5.5) which closely mimic the intracellular acidity (pH 4.5–5.5) of endosomes/lysosomes formed around drug-loaded nanocarriers after their endocytosis by cancer cells.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Mesoporous Materials and Catalysis · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. To · 2020
2. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing10.1186/s12967-023-04263-8 ↗
3. Repurposing metformin: an old drug with new tricks in its binding pockets10.1042/BJ20150497 ↗
4. Metformin: update on mechanisms of action and repurposing potential
5. Metformin in cancer treatment and prevention10.1146/annurev-med-062613-093128 ↗
6. Repurposing metformin for cancer treatment: current clinical studies10.18632/oncotarget.8194 ↗
7. Metformin and cancer: an existing drug for cancer prevention and therapy
8. Metformin reduces the risk of cancer in patients with type 2 diabetes: an analysis based on the Korean National Diabetes Program Cohort
9. Metformin and reduced risk of cancer in diabetic patients10.1136/bmj.38415.708634.F7 ↗
10. Metformin as an anticancer agent10.1016/j.tips.2018.07.006 ↗
11. Metformin targets multiple signaling pathways in cancer10.1186/s40880-017-0184-9 ↗
12. Metformin: is it a drug for all reasons and diseases?10.1016/j.metabol.2022.155223 ↗
13. Sustained in vitro delivery of metformin-loaded mesoporous silica nanoparticles for delayed senescence and stemness preservation of adipose-derived stem cells
14. Current perspective on the challenges in the development of metformin orally disintegrating tablets (ODTs)
15. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis10.7554/eLife.02242 ↗
16. Results from 11C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly10.1038/s41598-017-10010-z ↗
17. Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients10.1111/bcp.15546 ↗
18. Metformin accumulation correlates with organic cation transporter 2 protein expression and predicts mammary tumor regression in vivo10.1158/1940-6207.CAPR-16-0211-T ↗
19. The acidic microenvironment: is it a phenotype of all cancers? A focus on multiple myeloma and some analogies with diabetes mellitus10.3390/cancers12113226 ↗
20. The acidic tumor microenvironment as a driver of cancer10.1146/annurev-physiol-021119-034627 ↗
21. The acidic tumor microenvironment: a target for smart cancer nano-theranostics10.1093/nsr/nwx062 ↗
22. Smart pH-responsive nanomedicines for disease therapy10.1007/s40005-022-00573-z ↗
23. Stimuli-responsive liposomal nanoformulations in cancer therapy: pre-clinical & clinical approaches10.1016/j.jconrel.2022.08.001 ↗
24. Mesoporous silica nanoparticles: synthesis and multifaceted functionalization for controlled drug delivery
25. Nanotherapeutics of PTEN inhibitor with mesoporous silica nanocarrier effective for axonal outgrowth of adult neurons10.1021/acsami.6b06889 ↗
26. Ionic and thermo-switchable polymer-masked mesoporous silica drug-nanocarrier: high drug loading capacity at 10 °C and fast drug release completion at 40 °C10.1016/j.colsurfb.2016.04.023 ↗
27. PDA-based drug delivery nanosystems: a potential approach for glioma treatment10.2147/IJN.S378217 ↗
28. Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics10.1186/s12951-021-01131-9 ↗
29. Polydopamine-coated magnetic mesoporous silica nanoparticles for multimodal cancer theranostics10.1039/C8TB03021A ↗
30. Polydopamine-coated gold core/hollow mesoporous silica shell particles as a nanoplatform for multimode imaging and photothermal therapy of tumors10.1016/j.cej.2019.01.072 ↗
31. Polydopamine-engineered theranostic nanoscouts enabling intracellular HSP90 mRNAs fluorescence detection for imaging-guided chemo–photothermal therapy10.1002/adhm.202201615 ↗
32. Polydopamine-containing nano-systems for cancer multi-mode diagnoses and therapies: a review
33. Nanoparticles modified by polydopamine: working as “drug” carriers
34. Polydopamine-based nanomaterials and their potentials in advanced drug delivery and therapy10.1016/j.colsurfb.2020.111502 ↗
35. Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy10.1016/j.msec.2019.110103 ↗
36. Gold modified polydopamine coated mesoporous silica nano-structures for synergetic chemo-photothermal effect10.1016/j.colsurfb.2018.07.015 ↗
37. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy10.1016/j.jcis.2015.11.001 ↗
38. Application of polydopamine in tumor targeted drug delivery system and its drug release behavior10.1016/j.jconrel.2018.10.009 ↗
39. A polydopamine-based platform for anti-cancer drug delivery10.1039/C8BM01642A ↗
40. The versatile applications of polydopamine in regenerative medicine: progress and challenges10.1016/j.smaim.2022.11.005 ↗
41. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields10.1021/cr400407a ↗
42. Multifunctional polydopamine-based nanoparticles: synthesis, physico-chemical properties and applications for bimodal photothermal/photodynamic therapy of cancer10.1088/2399-7532/abf0fa ↗
43. Polydopamine surface-modified nanocarriers for improved anticancer activity: current progress and future prospects10.1016/j.onano.2022.100059 ↗
44. Intervention of polydopamine assembly and adhesion on nanoscale interfaces: state-of-the-art designs and biomedical applications10.1002/adhm.202002138 ↗
45. Stimuli-responsive silica silanol conjugates: strategic nanoarchitectonics in targeted drug delivery10.1002/smll.202301113 ↗
46. Mesoporous silica nanoparticles and mesoporous bioactive glasses for wound management: from skin regeneration to cancer therapy10.3390/ma14123337 ↗
47. Therapeutic potential of polymer-coated mesoporous silica nanoparticles10.3390/app10010289 ↗
48. A pH-responsive nanoplatform based on magnetic mesoporous silica nanoparticles for enhanced treatment of pancreatic cancer10.1021/acsanm.3c04596 ↗
49. Review on template removal techniques for synthesis of mesoporous silica materials10.1021/acs.energyfuels.1c04435 ↗
50. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?10.1039/D1CS00659B ↗
51. Multifunctional coatings hinging on the catechol/amine interplay
52. Polydopamine free radical scavengers10.1039/D0BM01070G ↗
53. Facile and rapid ultrasound-mediated synthesis of spherical mesoporous silica submicron particles with high surface area and worm-like mesoporosity10.1016/j.matlet.2020.128620 ↗
54. Facile and affordable process to control shell thickness of polydopamine-assisted polystyrene/silver core-shell particles10.1007/s13233-019-7154-9 ↗
55. Effect of polydopamine coating on improving photostability of polyphenylene sulfide fiber10.1007/s00289-016-1735-y ↗
56. Overcoming the trade-off relationship between mechanical and adhesive properties of acrylic pressure sensitive adhesive thin-film by reinforcing polydopamine-coated silica nanoparticles10.1016/j.polymer.2021.123937 ↗
57. Okyere · 2021
58. Glutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment10.1039/C9TB01400D ↗
59. Antioxidant cerium ions-containing mesoporous bioactive glass ultrasmall nanoparticles: structural, physico-chemical, catalase-mimic and biological properties10.1016/j.colsurfb.2021.111932 ↗
60. Physicochemical properties and methods for the determination of metformin hydrochloride (A Review)10.1007/s11094-021-02546-2 ↗
61. Metformin: an old drug for the treatment of diabetes but a new drug for the protection of the endothelium10.1159/000381643 ↗
62. Drug release and thermal properties of magnetic cobalt ferrite (CoFe2O4) nanocomposite hydrogels based on poly (acrylic acid-gN-isopropyl acrylamide) grafted onto gum ghatti10.1016/j.ijbiomac.2022.10.129 ↗
63. Vibrational spectra and thermodynamic analysis of metformin
64. Mixed-charge pseudo-zwitterionic mesoporous silica nanoparticles with low-fouling and reduced cell uptake properties10.1016/j.actbio.2018.12.012 ↗
65. One-pot synthesis of biodegradable polydopamine-doped mesoporous silica nanocomposites (PMSNs) as pH-sensitive targeting drug nanocarriers for synergistic chemo-photothermal therapy10.1039/C8RA07467D ↗
66. Kinetics of the functionalization of mesoporous silica nanoparticles: implications on surface group distributions, adsorption and catalysis10.1016/j.micromeso.2020.110276 ↗